GSK Patent-Cliff Exposure & CMS Drug Spending Portfolio
GSK (Philadelphia, PA): 71 reconciled FDA prescription therapies (60.6% 2025 to 2030 cliff risk), $16.94B 2024 CMS Part D & Medicaid spend, and 67 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Philadelphia, PA |
| Reconciled FDA Portfolio Therapies | 71 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 60.6% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $16.94B |
| 2024 Medicare Part D Spend | $13.84B |
| 2024 Medicaid Spend | $3.10B |
| California HCAI SB 17 Filings | 67 WAC filings (max 28.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.